[go: up one dir, main page]

AR109503A1 - Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento - Google Patents

Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento

Info

Publication number
AR109503A1
AR109503A1 ARP170102376A ARP170102376A AR109503A1 AR 109503 A1 AR109503 A1 AR 109503A1 AR P170102376 A ARP170102376 A AR P170102376A AR P170102376 A ARP170102376 A AR P170102376A AR 109503 A1 AR109503 A1 AR 109503A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
amino
trimetoxiestiril
metoxibencilsulfona
carboximethyl
Prior art date
Application number
ARP170102376A
Other languages
English (en)
Inventor
Manoj Maniar
Original Assignee
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59856606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR109503(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onconova Therapeutics Inc filed Critical Onconova Therapeutics Inc
Publication of AR109503A1 publication Critical patent/AR109503A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica, caracterizada porque comprende: a) (E)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, y sus sales farmacéuticamente aceptables; b) polietilenglicol básico pretratado de bajo peso molecular; c) pH sin diluir de alrededor de 11.0 a alrededor de 14.0; y d) menos de 5% de agua o disolución acuosa. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque dicho polietilenglicol básico pretratado de bajo peso molecular comprende uno o más de PEG 200, PEG 300, PEG 400 y PEG 600.
ARP170102376A 2017-04-13 2017-08-28 Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento AR109503A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762485355P 2017-04-13 2017-04-13

Publications (1)

Publication Number Publication Date
AR109503A1 true AR109503A1 (es) 2018-12-19

Family

ID=59856606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102376A AR109503A1 (es) 2017-04-13 2017-08-28 Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento

Country Status (19)

Country Link
US (1) US10098862B1 (es)
EP (3) EP3733163B8 (es)
JP (1) JP7202313B2 (es)
KR (1) KR102643626B1 (es)
CN (2) CN116637095A (es)
AR (1) AR109503A1 (es)
AU (2) AU2018253291B2 (es)
BR (1) BR112019021445A2 (es)
CA (1) CA3058664A1 (es)
CL (1) CL2019002899A1 (es)
CO (1) CO2019011299A2 (es)
EA (1) EA201992436A1 (es)
ES (3) ES2926042T3 (es)
IL (2) IL289806B2 (es)
MX (1) MX2022011860A (es)
TW (2) TWI759459B (es)
UY (1) UY37380A (es)
WO (2) WO2018190897A1 (es)
ZA (2) ZA201906671B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382877B2 (en) 2017-04-13 2022-07-12 Onconova Therapeutics, Inc. Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US12156856B2 (en) 2017-04-13 2024-12-03 Traws Pharma, Inc. Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373945T3 (es) 2002-02-28 2012-02-10 Temple University - Of The Commonwealth System Of Higher Education Bencilsulfonas de (e)-2,6-dialcoxiestirilo amino sustituido sustituidas en 4 para tratar trastornos proliferativos.
CA2574491C (en) 2004-07-19 2011-05-24 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2,6-dialkoxystryryl 4-substituted benzylsulfones
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
JP2010515772A (ja) * 2007-01-16 2010-05-13 オンコノバ・セラピューティックス・インコーポレーテッド （ｅ）−２，６−ジアルコキシスチリル４−置換ベンジルスルホン類の非経口投与用製剤
WO2013123227A1 (en) * 2012-02-14 2013-08-22 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer

Also Published As

Publication number Publication date
IL269757A (en) 2019-11-28
CL2019002899A1 (es) 2020-02-28
IL289806B1 (en) 2024-02-01
WO2018191634A4 (en) 2019-06-20
TWI809721B (zh) 2023-07-21
ES2993599T3 (en) 2025-01-02
TW201836597A (zh) 2018-10-16
MX2022011860A (es) 2022-10-20
CO2019011299A2 (es) 2020-02-18
WO2018191634A3 (en) 2019-04-11
CA3058664A1 (en) 2018-10-18
IL289806B2 (en) 2024-06-01
IL269757B (en) 2022-08-01
JP2020516665A (ja) 2020-06-11
US10098862B1 (en) 2018-10-16
KR20190134705A (ko) 2019-12-04
EA201992436A1 (ru) 2020-03-30
ES2941538T3 (es) 2023-05-23
CN116637095A (zh) 2023-08-25
EP3609471A2 (en) 2020-02-19
AU2018253291A1 (en) 2019-10-24
EP3733163A1 (en) 2020-11-04
US20180296513A1 (en) 2018-10-18
CN110536678A (zh) 2019-12-03
ZA202107580B (en) 2023-11-29
EP4193988A1 (en) 2023-06-14
ES2926042T3 (es) 2022-10-21
JP7202313B2 (ja) 2023-01-11
AU2024205164A1 (en) 2024-08-15
AU2018253291B2 (en) 2024-05-02
BR112019021445A2 (pt) 2020-05-05
WO2018190897A1 (en) 2018-10-18
TWI759459B (zh) 2022-04-01
UY37380A (es) 2018-10-31
EP3733163B1 (en) 2022-06-08
EP3733163B8 (en) 2022-09-28
EP3609471B1 (en) 2023-01-04
TW202222303A (zh) 2022-06-16
EP4193988B1 (en) 2024-06-05
ZA201906671B (en) 2022-03-30
KR102643626B1 (ko) 2024-03-06
WO2018191634A2 (en) 2018-10-18
IL289806A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
HRP20210342T1 (hr) Pripravci glikopeptida
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
MX387604B (es) Formulaciones cannabinoides estables.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
IL283539A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
AR100453A1 (es) Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
EA201790223A1 (ru) Водный препарат, содержащий парацетамол и ибупрофен
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
PE20180039A1 (es) Piroglutamato de vortioxetina
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
MX2016013559A (es) Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение
AR109503A1 (es) Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento
MX387472B (es) Composiciones para el cuidado bucal y sistema para dispensar las mismas.
EA201792121A1 (ru) Фармацевтические солевые формы ингибитора семикарбазидчувствительной аминоксидазы (ssao)
CY1124609T1 (el) Υγρη συνθεση ανθρωπινου ινωδογονου
UA117200C2 (uk) Водні фармацевтичні композиції для місцевого застосування у ротовій порожнині, що містять флурбіпрофен і декспантенол
MX2017007847A (es) Composicion de cuidado oral.

Legal Events

Date Code Title Description
FB Suspension of granting procedure